TrackPaw Scientific secured €2.3 million in funding co-led by FSG Fund II and Industrifonden, with an additional €0.5 million from existing shareholders. The funding will support transition from beta trials with select pharmaceutical partners to a full commercial launch in the Nordics in the second half of 2026. TrackPaw combines machine learning and sensor technology to monitor animal behavior and weight in real time, delivering objective, high-resolution data across multiple disease areas. The solution aims to reduce subjective conclusions in preclinical studies, improve animal welfare, accelerate access to effective medicines, and lower costs for large pharma.
Founded in 2022 and headquartered in Lund, Sweden, TrackPaw Scientific is tackling one of the major challenges in clinical development: the high failure rate of over 90% due to subjective and inconsistent conclusions from animal-based preclinical studies. By integrating machine learning and sensor technology, TrackPaw monitors animal behavior and weight in real time, providing scientists with objective, high-resolution data across a wide range of disease areas. This innovation leads to more robust study outcomes, improved animal welfare, and faster access to effective new medicines.
We believe TrackPaw has assembled an outstanding team and a truly remarkable product that stands to transform the landscape of preclinical research. By delivering more reliable and sustainable data, they not only enhance the quality of scientific outcomes but also drive significant cost savings for major pharma players. This isn't just an exciting initiative; it's a game changer that sets a new standard for the industry and elevates animal welfare to new heights.
Collection
[
|
...
]